Entrada Therapeutics (NASDAQ:TRDA) used a presentation at Guggenheim’s 2026 Emerging Outlook Biotech Summit to outline its pipeline focus on intracellular therapeutics and to preview multiple clinical ...
IMPACT DUCHENNE is a Phase 3 randomized, double-blind, placebo-controlled trial to evaluate the efficacy of a single dose of ...
The health secretary turned his agencies toward skepticism of processed food and vaccines, but he’s faced pushback at every turn — including from Republicans.
A milestone in the treatment of Duchenne muscular dystrophy (DMD) passed recently with remarkably little public notice. That ...
A FUNDRAISING event held at a gym to support a young boy with a muscle-wasting condition raised more than £4,000. AGV HQ, in Newtown Road, hosted the “Ben vs Duchenne 79 Team Challenge” on Sunday.
With the writing apparently on the wall, PTC Therapeutics has called off its latest bid for FDA approval of its Duchenne muscular dystrophy (DMD) drug Translarna. | Late Thursday, PTC revealed that ...
A preclinical study led by the Germans Trias i Pujol Research Institute (IGTP), in collaboration with the Institut de ...
In a statement, PTC's chief executive, Matthew Klein, said the company had decided to pull the filing for Translarna (ataluren) as a treatment for nonsense mutation DMD after the FDA said it was ...
Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® ...
Regenxbio advances RGX-314 and RGX-202 pipelines for AMD and Duchenne while navigating recent FDA program setbacks. Read why ...
Solid Biosciences Inc. is a Strong Buy driven by positive FDA alignment on phase 3 IMPACT DUCHENNE trial for SGT-003. Read ...
With a clutch of key data and planned regulatory applications this year from Avidity Biosciences, REGENXBIO and Capricor ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results